Frequently Asked Questions
The market is segmented based on , By Symptoms (Chronic Excessive Thirst (Polydipsia), Excessive Urine Production (Polyuria), and Others), Drug Type (Demeclocycline, Ofloxacin, and Orlistat), Diagnosis (X-ray Scans, Computed Tomography (CT Scan), Ultrasound, and Magnetic Resonance Imaging (MRI)), End Users (Hospitals, Clinics, Pharmaceutical Companies, and Others) – Industry Trends and Forecast to 2031.
.
The Global Nephrogenic Diabetes Insipidus Market size was valued at USD 333.41 USD Billion in 2023.
The Global Nephrogenic Diabetes Insipidus Market is projected to grow at a CAGR of 6.2% during the forecast period of 2024 to 2031.
The major players operating in the market include Allergan (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Taj Pharmaceuticals Limited (India), Otsuka Holdings Co. Ltd. (Japan), and Azevan Pharmaceuticals, Inc. (U.S.).
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
